Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 7

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 7
---
 rights or break - up fee if an alternative proposal materializes ▪ Ability for existing stockholders to realize standalone value consistent with Alcon's offer is highly unlikely 1 STAAR does not have the scale or resources to be a profitable, high - growth standalone company 1 Alcon, as the global leader in eye care, is best suited to maximize the value of EVO ICL ▪ Business fundamentals have materially changed since Alcon's initial offer in October 2024 and the adjustment in value is appropriate given true product demand. The market made that adjustment correctly , and absent the proposed merger shareholders should expect the stock to return to that value indefinitely 1 o Company reduced its sales guidance from a 2023 - 26 CAGR of 15 - 20% 2 to an anemic 2% 3 o China consumer confidence has dropped and remained depressed since 2022 4 o Competitive environment in China expected to intensify with new entrants 3 o Cutting costs is expected to stunt growth, not accelerate 1 o Q3 2025 growth does not indicate a material change from recent lackluster performance 5

4 Current valuation reflects reality Activist stockholders a re engineering a silent takeover Merger is best option for stockholders

5 Downward correction in valuation, rebasing off STAAR’s underlying performance, is reflected in both Alcon’s offer and the market … 213 270 319 525 525 562 601 643 688 2021 22 23 338 338 24e 25e 26e 27f 28f 29f 30f +18% 1. STAAR Management Presentation: Alcon Merger Maximizes Value for Stockholders of STAAR Surgical – September 2025 2. STAAR Investor Presentation, March 2024; $525m in 2026e taken as midpoint of $500 - 550m range 3. Illustrative: assumes 7% CAGR growth off of STAAR 2026 guidance Actual 1 “Vision 2026” STAAR 2 Illustrative forecast @ 7% 3 Prior Guidance STAAR ICL Sales – Q1 2024 , $m Actual 1 STAAR Latest Forcast 1 Current Guidance STAAR ICL Sales – Q3 2025 , $m 213 270 319 525 525 688 313 313 260 340 364 389 417 446 2021